{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Campath-1+H+%28Alemtuzumab%29",
    "query": {
      "intervention": "Campath-1 H (Alemtuzumab)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T06:49:45.180Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00383448",
      "title": "HSCT for High Risk Inherited Inborn Errors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adrenoleukodystrophy",
        "Metachromatic Leukodystrophy",
        "Globoid Cell Leukodystrophy",
        "Tay Sachs Disease",
        "Sandhoffs Disease",
        "Wolman Disease",
        "I-Cell Disease",
        "Sanfilippo Syndrome",
        "GM1 Gangliosidosis"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Total body Irradiation",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "mycophenylate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine A",
          "type": "DEVICE"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 38,
      "start_date": "2006-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00383448"
    },
    {
      "nct_id": "NCT01652092",
      "title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "SCID",
        "Omenn's Syndrome",
        "Reticular Dysgenesis",
        "Wiskott-Aldrich Syndrome",
        "Bare Lymphocyte Syndrome",
        "Common Variable Immunodeficiency",
        "Chronic Granulomatous Disease",
        "CD40 Ligand Deficiency",
        "Hyper IgM Syndrome",
        "X-linked Lymphoproliferative Disease",
        "Hemophagocytic Lymphohistiocytosis",
        "Griscelli Syndrome",
        "Chediak-Higashi Syndrome",
        "Langerhan's Cell Histiocytosis"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab 0.3 mg",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine phosphate 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab 0.2 mg",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine phosphate 30 mg",
          "type": "DRUG"
        },
        {
          "name": "MESNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 57,
      "start_date": "2012-09-04",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652092"
    },
    {
      "nct_id": "NCT01213329",
      "title": "Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2006-02",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01213329"
    },
    {
      "nct_id": "NCT00167661",
      "title": "Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Disorder Related to Renal Transplantation"
      ],
      "interventions": [
        {
          "name": "Campath-1H",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "18 Months to 18 Years"
      },
      "enrollment_count": 33,
      "start_date": "2004-06",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2020-09-21",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167661"
    },
    {
      "nct_id": "NCT00038844",
      "title": "Safety and Efficacy of Campath in Nonmyeloablative Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Campath-1 H (Alemtuzumab)",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 65,
      "start_date": "2001-06",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2011-11-02",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038844"
    },
    {
      "nct_id": "NCT00031005",
      "title": "Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukocyte-Adhesion Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "modified stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2002-02",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031005"
    },
    {
      "nct_id": "NCT00023192",
      "title": "Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "T-Cell Depleted & CD34+Select/w/StemCell Enriched Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "2001-08",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023192"
    },
    {
      "nct_id": "NCT00426517",
      "title": "Donor Stem Cell Transplantation for Congenital Immunodeficiencies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Inherited Immune Deficiencies"
      ],
      "interventions": [
        {
          "name": "Campath 1H",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Horse Anti-human Thymocyte Globulin (h-ATG)",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus or equivalent based on response",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 48,
      "start_date": "2007-01-19",
      "completion_date": "2019-11-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426517"
    },
    {
      "nct_id": "NCT00495755",
      "title": "Campath in Chronic GVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Graft-vs.-Host Disease"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab (Campath)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2007-07",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2013-08-09",
      "last_synced_at": "2026-10-08T06:49:45.180Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00495755"
    }
  ]
}